newsfilter
← Latest News
GlobeNewswire·

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

RNXT
  • RenovoRx reported third quarter 2025 revenue of approximately $266,000, bringing year-to-date revenue through September 30, 2025, to approximately $900,000.
  • The company's cash and cash equivalents balance stood at $10.0 million as of September 30, 2025.
  • RenovoRx expanded its customer base from five approved cancer centers at the start of 2025 to 14 centers by November 7, 2025, with 10 additional centers having requested quotes.
  • The company hired Philip Stocton as Senior Director of Sales & Market Development in August 2025, alongside two regional sales managers, to drive commercial growth.
  • The Phase III TIGeR-PaC clinical trial is on track to complete enrollment in early 2026, with final data readout expected in 2027.
  • A new post-marketing registry study launched in September 2025 to generate real-world evidence on the RenovoCath device, with sites including the University of Vermont Cancer Center.
  • Research and development expenses were $1.7 million for the quarter, while selling, general, and administrative expenses rose to approximately $1.7 million.
  • The company reported a net loss of $2.9 million for the quarter ended September 30, 2025, compared to $2.5 million in the prior year period.
  • Shares outstanding totaled approximately 36.6 million as of November 7, 2025.
  • RenovoRx estimates the initial total addressable market for the RenovoCath device at approximately $400 million in peak annual U.S. sales.
  • A conference call regarding these financial results is scheduled for Thursday, November 13, 2025, at 4:30 p.m. ET.